TELA Bio, Inc. - TELA STOCK NEWS

TELA Bio, Inc. has appointed Roberto Cuca as the new Chief Operating Officer (COO) and Chief Financial Officer (CFO). With over 25 years of experience in the healthcare sector, including leadership roles at OraSure Technologies and Trevana, Cuca's expertise is expected to bolster TELA's operations and financial management. On his appointment date, he was granted an option to purchase 144,000 shares of TELA's common stock, indicating the company's confidence in his capabilities. The move aims to drive growth and enhance TELA’s strategic execution in tissue reinforcement technologies.

TELA Bio recently shared promising clinical results at the 2021 Society of American Gastrointestinal and Endoscopic Surgeons meeting, highlighting advancements in hernia repair solutions.

Key findings include a 2.7% recurrence rate and 1.8% surgical site occurrence rate using the OviTex in robotic-assisted procedures, demonstrating its efficacy as a natural repair alternative.

Further studies indicate a 1.3% recurrence rate across 619 implants with a unique surgical technique, underscoring the potential of OviTex in complex repairs.

TELA Bio (NASDAQ: TELA) announces three poster presentations highlighting the effectiveness of its OviTex Reinforced Tissue Matrix for hernia repairs at the SAGES conference from August 31 to September 3, 2021. The presentations will feature collaborative research from over 100 surgeons, showcasing innovative approaches such as the Reinforced Biologic Augmented Repair (ReBAR) technique. The company aims to provide advanced, biologically effective solutions that enhance surgical outcomes while minimizing the use of permanent synthetic materials.

On August 11, 2021, TELA Bio, Inc. (Nasdaq: TELA) announced its second quarter 2021 financial results, reporting a revenue of $7.6 million, reflecting a 116% year-over-year increase and a 29% rise from the previous quarter. The growth was attributed to increased demand for OviTex® products, particularly in robotic-assisted procedures. Gross profit improved to 67% of revenue. However, TELA incurred a net loss of $8.3 million, up from $6.1 million in Q2 2020. The company raised its revenue guidance for 2021 to between $28 million and $30 million, indicating a growth forecast of 54% to 65%.

MALVERN, Pa., Aug. 03, 2021 – TELA Bio, Inc. (NASDAQ: TELA) has announced its participation in Canaccord Genuity’s 41st Annual Growth Conference. Management will present on August 12, 2021, at 2:00 PM EDT. The company specializes in innovative tissue reinforcement materials aimed at enhancing soft tissue reconstruction outcomes. TELA’s OviTex® and OviTex PRS products are designed to improve hernia repair and abdominal wall reconstruction processes while minimizing reliance on synthetic materials.

TELA Bio, Inc. (NASDAQ: TELA), a medical technology company, announced it will report its second quarter 2021 financial results on August 11, 2021, at 4:30 p.m. ET. This report will cover financial highlights and provide a corporate update. TELA Bio specializes in innovative tissue reinforcement solutions for soft tissue reconstruction, aiming to improve patient outcomes while reducing the use of permanent synthetic materials. Their OviTex® products are designed for hernia repair and abdominal wall reconstruction.

TELA Bio, Inc. (NASDAQ: TELA) announces the successful completion of Europe's first minimally invasive hernia repair using its OviTex LPR Reinforced Tissue Matrix by Mr. Paul Wilson, Consultant General Surgeon at University Hospitals of Morecambe Bay NHS Foundation Trust. This milestone represents the initial phase of a broader commercial launch slated for Q4 2021 across Europe. The OviTex LPR aims to enhance surgical approaches for complex hernia procedures, meeting rising demand for minimally invasive solutions while improving clinical outcomes.

MALVERN, Pa., June 14, 2021 – TELA Bio, Inc. (NASDAQ: TELA) announced its participation in the JMP Securities Life Sciences Conference. The presentation is scheduled for June 16, 2021, at 11:30 AM EDT. Interested parties can access the live and archived webcast at ir.telabio.com. TELA Bio focuses on innovative tissue reinforcement materials for soft tissue reconstruction, aiming to enhance clinical outcomes and minimize the use of permanent synthetic materials.

TELA Bio, Inc. (NASDAQ: TELA) announced the appointment of John Nosenzo, former Chief Commercial Officer at Bioventus Inc., to its board of directors, effective June 2, 2021. This change coincides with the departure of board member Adele Olivia, resulting in a board of seven directors, six of whom are independent. Nosenzo brings extensive healthcare marketing and sales experience, which could positively impact TELA's strategic direction. The company focuses on innovative tissue reinforcement materials for soft tissue reconstruction, aiming to improve clinical outcomes.